Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Do dopamine agonists provide neuroprotection?

M Yamamoto1

  • 1Department of Neurology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.

Neurology
|August 26, 1998
PubMed
Summary

Current research indicates that while dopamine agonists show promise in lab studies, there is no clinical evidence supporting their direct neuroprotective effects for Parkinson's disease (PD). Further investigation is needed to confirm benefits in human patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of scavenger receptors on renal cell carcinoma cells in vitro.

Biochemical and biophysical research communications·1992
Same author

Insulin administration induces capillary growth in brown adipose tissue of heat-exposed rats.

Comparative biochemistry and physiology. Comparative physiology·1992
Same author

[Structure and tissue-specific expression of erythroid type delta-aminolevulinate synthase: relation to erythroid-specific transcription factors].

Seikagaku. The Journal of Japanese Biochemical Society·1992
Same author

Electron microscope observations on the formation of primitive villi in rat small intestine with special reference to intercellular junctions.

Archives of histology and cytology·1992
Same author

Alpha-1-antichymotrypsin variant detected by PCR-single strand conformation polymorphism (PCR-SSCP) and direct sequencing.

Human genetics·1992
Same author

Characterization of a fission yeast gene, gpa2, that encodes a G alpha subunit involved in the monitoring of nutrition.

Genes & development·1992

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Neurology

Background:

  • Dopamine (DA) agonists like pramipexole, bromocriptine, and pergolide have demonstrated potential neuroprotective effects in experimental settings.
  • The hypothesis that DA agonists offer neuroprotection is attractive, partly due to links with the oxidative stress theory of neurodegeneration.
  • Despite widespread belief among neurologists, the neuroprotective role of DA agonists in Parkinson's disease (PD) remains debated.

Purpose of the Study:

  • To review and critically evaluate experimental evidence for the neuroprotective effects of DA agonists.
  • To examine the clinical justification for using DA agonists as neuroprotective agents in Parkinson's disease.
  • To assess the relevance of studies on DA agonist monotherapy, particularly de novo treatment.

Main Methods:

  • Review of experimental studies on DA agonists and their neuroprotective effects.
  • Focus on clinical data, especially from de novo Parkinson's disease treatment studies.
  • Analysis of studies examining DA agonist monotherapy versus combination therapy.

Main Results:

  • Some studies indicate that DA agonists can delay the initiation of levodopa therapy in Parkinson's disease patients.
  • However, long-term monotherapy with DA agonists has proven difficult to sustain in clinical practice.
  • The reviewed studies did not provide conclusive clinical evidence for direct neuroprotective actions of DA agonists against PD progression.

Conclusions:

  • Currently, there is a lack of robust clinical evidence to support the direct neuroprotective effects of dopamine agonists in Parkinson's disease.
  • While DA agonists may offer symptomatic relief or delay other treatments, their role in halting or reversing neurodegeneration in PD is unproven.
  • Further rigorous clinical trials are necessary to ascertain the true neuroprotective capacity of DA agonists in Parkinson's disease patients.

Related Experiment Videos